Patent ID: 11965875
Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G | IPC C  G

Claim 5:
6. A method of screening an agent for tumor immunotherapy, comprising assessing the effect of an analyte on tumor immune cells, the method comprises the steps of:
a) assessing the effect of the analyte on target cells, the target cells are B cells,
b) assessing the effect of the analyte on non-target cells; and
c) assessing the effect of the analyte on tumor immune infiltration;
wherein step a) comprises:
a-1) assessing the effect of the analyte on B cells of an immune cell line, and
a-2) assessing the effect of the analyte on B cells of primary immune cells;
wherein the assessment result is divided into two levels of positive (+) and negative (−), and the analyte with a negative assessment result is directly determined as a negative analyte without performing any subsequent steps,
step a-2) is continued for the analyte with a positive assessment result in the step a-1), and the assessment result is divided into two levels of either positive (+) or negative (−); the analyte with a negative assessment result in step a-2) is directly determined as a negative analyte without performing any subsequent steps;
step b) comprises assessing the effect of the analyte on immune cell line non-target cells, and/or assessing the effect of the analyte on primary immune cell non-target cells,

d) determining the analyte with a level of positive (+) after step a-2) as the agent for tumor immunotherapy.